If it feels like you’ve been hearing from the head of the Food and Drug Administration a lot lately, you’re not imagining it.

It’s a rare day here at STAT when we don’t receive in our inboxes a “Statement from FDA Commissioner Scott Gottlieb, M.D.” — or at least find him prominently quoted in another new FDA press release. Then there are all his blog posts. His speeches. His congressional testimony. And, of course, his tweets.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Now that you’ve gotten mired in Gottlieb word count, please address the content. I’d say, based on STAT News reportage and those of many other outlets, the man has ‘something worthwhile to say.’ On the other hand, maybe I’m only seeing the ‘cream of the crop’?

Your daily dose of news in health and medicine

Privacy Policy